A detailed history of Goldman Sachs Group Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 10,682,319 shares of ABBV stock, worth $1.88 Billion. This represents 0.35% of its overall portfolio holdings.

Number of Shares
10,682,319
Previous 11,610,889 8.0%
Holding current value
$1.88 Billion
Previous $1.99 Billion 5.93%
% of portfolio
0.35%
Previous 0.34%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $152 Million - $185 Million
-928,570 Reduced 8.0%
10,682,319 $2.11 Billion
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $422 Million - $493 Million
2,725,088 Added 30.67%
11,610,889 $1.99 Billion
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $277 Million - $316 Million
-1,734,645 Reduced 16.33%
8,885,801 $1.62 Billion
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $15.6 Million - $17.6 Million
-113,628 Reduced 1.06%
10,620,446 $1.65 Billion
Q3 2023

May 14, 2024

BUY
$133.59 - $154.65 $15.2 Million - $17.6 Million
113,628 Added 1.07%
10,734,074 $1.6 Billion
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $189 Million - $219 Million
1,413,745 Added 15.17%
10,734,074 $1.6 Billion
Q2 2023

May 14, 2024

SELL
$132.51 - $164.9 $106 Million - $132 Million
-799,125 Reduced 7.9%
9,320,329 $1.26 Billion
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $106 Million - $132 Million
-799,125 Reduced 7.9%
9,320,329 $1.26 Billion
Q1 2023

May 14, 2024

BUY
$144.61 - $166.54 $185 Million - $214 Million
1,282,296 Added 14.51%
10,119,454 $1.61 Billion
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $185 Million - $214 Million
1,282,296 Added 14.51%
10,119,454 $1.61 Billion
Q4 2022

May 14, 2024

SELL
$138.31 - $165.87 $79.5 Million - $95.3 Million
-574,540 Reduced 6.1%
8,837,158 $1.43 Billion
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $79.5 Million - $95.3 Million
-574,540 Reduced 6.1%
8,837,158 $1.43 Billion
Q3 2022

May 14, 2024

BUY
$134.21 - $153.93 $107 Million - $123 Million
796,517 Added 9.25%
9,411,698 $1.26 Billion
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $107 Million - $123 Million
796,517 Added 9.25%
9,411,698 $1.26 Billion
Q2 2022

May 14, 2024

SELL
$137.62 - $174.96 $276 Million - $351 Million
-2,005,265 Reduced 18.88%
8,615,181 $1.32 Billion
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $84.1 Million - $107 Million
-610,746 Reduced 6.62%
8,615,181 $1.32 Billion
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $56.5 Million - $70.1 Million
-428,133 Reduced 4.43%
9,225,927 $1.5 Billion
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $24 Million - $30.4 Million
-223,702 Reduced 2.26%
9,654,060 $1.31 Billion
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $1.05 Billion - $1.19 Billion
9,877,762 New
9,877,762 $1.07 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.